Back to Results
First PageMeta Content
Anticoagulants / Morpholines / Rivaroxaban / Thiophenes / Pharmacology / Acute coronary syndrome / Placebo / Medicine / Health / Clinical research


Missing Data for Rivaroxaban ATLAS ACS 2 TIMI 51 Follow‐up study and sensitivity analyses Xiang Sun, PhD Janssen Research & Development LLC of Johnson & Johnson
Add to Reading List

Document Date: 2014-11-30 21:07:13


Open Document

File Size: 245,34 KB

Share Result on Facebook

City

Washington DC / Wuppertal / /

Company

Johnson & Johnson / Bayer / PhD Janssen Research & Development LLC / Statistics Collaborative Inc. / ITT / /

Country

Germany / United States / /

Event

FDA Phase / /

Facility

University of Michigan Julia Wang1 / /

MedicalCondition

Acute Coronary Syndrome / Thrombolysis In Myocardial Infarction / All Cause Stroke / /

Organization

University of Michigan / Harvard Medical School / FDA / Little Richard D. Remington Distinguished University / Advisory Committee / /

Person

Richard D. Remington / Nancy Cook / Xiang Sun / /

Position

Professor of Biostatistics / Professor of Medicine / /

Product

Anti-Xa Therapy / /

ProgrammingLanguage

DC / /

SocialTag